News
Employers face rising GLP-1 demand. Here are tips to manage costs while maintaining care access.
The state’s largest commercial health insurer will stop covering a popular class of prescription drugs for weight loss, ...
The growing number of Australians with obesity is causing economic damage but should the taxpayer fund weight-loss drugs?
Some of the more than a dozen states that cover the high cost of GLP-1 drugs like Wegovy, Ozempic and Zepbound through Medicaid or state employee insurance programs are scrambling to lessen the ...
Novo Nordisk , the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil ...
The Associated Press on MSN11d
The skyrocketing cost of weight-loss drugs has state Medicaid programs looking for a solutionSome of the more than a dozen states that cover the high cost of GLP-1 drugs like Wegovy, Ozempic and Zepbound through ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results